Mode
Text Size
Log in / Sign up
Phase 2 N=88 Randomized Quadruple-blind Treatment

Effectiveness of Clonidine, Dexmedetomidine, and Fentanyl Adjuncts for Labor Epidural Analgesia

Pregnancy Related

Enrolled (actual)
88
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Pain Burden, AUC (30 Minutes) — 101; 67; 39 pain units*minutes — p=0.226

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Clonidine (Drug); Dexmedetomidine (Drug); Fentanyl (Drug); Ropivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Grace Lim, MD, MS
Primary completion
Jul 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Burden, AUC (30 Minutes)
101; 67; 39 0.226
SECONDARY
Pain Burden, AUC (120 Minutes)
133; 67; 45 0.16
SECONDARY
Pain Scores
1.7; 0.8; 0.5 0.22
SECONDARY
Pain Scores
1.7; 0.8; 0.5 0.22
SECONDARY
Pain Scores
1.7; 0.8; 0.5 0.22
SECONDARY
Cesarean Delivery
3; 1; 3 0.28
SECONDARY
Hypotension
13; 10; 11 0.83
SECONDARY
Nausea
5; 4; 5 0.01 sig
SECONDARY
Vomiting
1; 0; 1 0.36
SECONDARY
Shivering
6; 4; 7 0.36
SECONDARY
Pruritus
3; 0; 5 0.54
SECONDARY
Patient Treatment Satisfaction
10; 10; 10 0.58
SECONDARY
Newborn Apgar Score
9; 8; 8.5 0.98

Summary

The purpose of this randomized controlled trial is to compare the effectiveness of epidural clonidine, dexmedetomidine, or fentanyl adjuncts for labor analgesia.

Eligibility Criteria

Pregnant minors were not enrolled in this trial.

Inclusion Criteria

  • Pregnant women greater than 18 years of age
  • American Society of Anesthesiologists (ASA) Physical Status 2 or 3
  • Term pregnancy (greater than 37 gestational weeks)
  • Planning epidural labor analgesia
  • Singleton pregnancy
  • Vertex presentation
  • Planned vaginal delivery

Exclusion Criteria

  • Pre-eclampsia with or without severe features
  • New initiation of antihypertensive agent within 24 hours prior to enrollment
  • Uncontrolled systemic comorbidities [i.e., diabetes, hepatic, renal or cardiac]
  • Known or suspected fetal abnormalities
  • Allergy to study agents
  • Contra-indication to neuraxial anesthesia
  • Inability to communicate or participate in study procedures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05487196). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search